BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase I (World)
$1 Billion Oncology Alliance Between Menarini Group & Oxford BioTherapeutics Initiates First-In-Human Study Of Enhanced Antibody For Treatment Of Acute Myeloid Leukemia 11/25/2014
Synthon Initiates Treatment Of First Patients In Phase I Trial Of Anti-HER2 ADC SYD985 Based On Its Proprietary Linker-Drug Platform 11/25/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 11/25/2014
Transition Therapeutics Inc. (TTH.TO)' ELND005 Showed No Prolongation Of QT Interval 11/24/2014
Admedus HPV Vaccine Heads To The Clinic 11/24/2014
OncoMed Pharmaceuticals, Inc. (OMED) Presents New Clinical And Biomarker Data From Its Tarextumab And Demcizumab Clinical Trials At The European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium 11/24/2014
Transition Therapeutics Inc. (TTH.TO) Announces Results From ELND005 Clinical Study In Adults With Down Syndrome 11/20/2014
Themis Bioscience’s Vaccine Against Chikungunya Successful In Phase 1 11/20/2014
BerGenBio AS Receives Orphan-Drug Designation From FDA For BGB324 In The Treatment Of Acute Myeloid Leukaemia 11/19/2014
Clovis Oncology (CLVS) Release: Interim Data From Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling And Durable Clinical Activity And Progression-Free Survival (PFS) In Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) 11/19/2014
3-V Biosciences Announces Presentation Of First Human Clinical Data For Lead Oral FASN Inhibitor Candidate At European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research 2014 11/19/2014
The Lancet Neurology Publishes Prana’s Huntington Disease Trial 11/18/2014
Agios Pharmaceuticals (AGIO) Announces Early Phase 1 Data Showing Clinical Activity Of AG-120 As A Single Agent In Advanced Acute Myeloid Leukemia (AML) 11/18/2014
Canadian Institutes Of Health Research Release: Canada Begins Ebola Vaccine Trial 11/14/2014
Cell Source's Megadose Drug Combination Receives Regulatory Approval In Italy To Commence Human Clinical Trials 11/13/2014
Oncoethix Starts Phase 1b Trials Of OTX015 In The Treatment Of Advanced Solid Tumors (OTX015_107) And Glioma (OTX015_108) 11/12/2014
R-Tech Ueno: Completion Of A Phase I/II Clinical Study Of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) In The U.S. For The Treatment Of Severe Dry Eye 11/10/2014
BioLineRx Ltd. Announces Successful Final Results Of Phase 1/2 Study For Novel Celiac Treatment 11/5/2014
BerGenBio AS Announces First Patient Dosed in BGB324 AML Trial 11/4/2014
MorEx Extends Phase I MTL-005 Radiation Enhancer Head & Neck Cancer Trial 11/3/2014
Suven Life Sciences Ltd Release: SUVN-G3031 For Cognition In Alzheimer’s Disease Commenced Phase 1 Clinical Trial In U.S.A. Under US-IND 123179 11/3/2014
Kiadis Pharma's Lead Product ATIR™ Granted Orphan Drug Designation By European Medicines Agency For The Treatment Of Acute Myeloid Leukemia 10/30/2014
Osteros Biomedica Announce Initiation Of A Phase I Clinical Trial 10/28/2014
TxCell Achieves Positive Results For Col-Treg In A Model Of Autoimmune Uveitis 10/28/2014
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/28/2014
uniQure Release: AIPGENE Consortium Presents 1 Year Follow-Up Clinical Data From Acute Intermittent Porphyria Phase I Clinical Trial Using AAV5-PBGD Gene Therapy Candidate 10/27/2014
Trinity Biotech (TRIB) Temporary Suspends Meritas Troponin Trials 10/23/2014
Novartis AG (NVS)'s Leukemia Drug CTL01 Clears Cancer In 90 Percent Of Patients 10/20/2014
MediGene, Inc. Announces Publication In Cancer Immunology, Immunotherapy On DC Vaccine Development For A Phase 1/2 Trial In Acute Myeloid Leukemia 10/16/2014
ActoGeniX Announces Positive Results From A Phase 1 Study Of AG014; Oral Capsule Administration Of An Anti-TNF-Alpha Antibody For The Treatment Of Inflammatory Bowel Disease 10/15/2014
Scancell Release: AGM Research And Development Update Highlights Progress In Both SCIB1 Clinical Trial And Moditope® Platform 10/14/2014
EU-Funded Consortium Led By immatics biotechnologies GmbH And BioNTech To Advance A Novel Class Of Fully Personalized Therapeutic Cancer Vaccines Into Clinical Trials For Brain Cancer 10/14/2014
Mali Health Workers Get Experimental GlaxoSmithKline (GSK) Ebola Vaccine 10/13/2014
Public Health Agency of Canada Release: Canadian Ebola Vaccine Trials Begin 10/13/2014
PharmaEngine, Inc. Will Join Nanobiotix' Pivotal Trial For NBTXR3 In Soft Tissue Sarcoma To Accelerate Its Development In Asia-Pacific 10/8/2014
Debiopharm Group™ Announces Progress In Phase I Single And Multiple Ascending Dose Study Of Debio 1450, Its Potent Anti-Staphylococcal Agent 10/7/2014
Novaliq GmbH Reports Positive Results From Cyclasol® (Cyclosporin Solution) Eye Drops Repeated And Ascending Dose Phase 1 Study 9/23/2014
First European Patients Enrolled In QT QT Vascular's ENDURE Trial 9/16/2014
United Therapeutics Corporation (UTHR) Advances To Second Cohort In Phase I Trial Of Pluristem Therapeutics (PSTI)'s PLX-PAD Cells For Treatment Of Pulmonary Arterial Hypertension 9/8/2014
GlaxoSmithKline (GSK)'s Ebola Vaccine To Be Tested For Safety In Humans As Early As Next Week 8/28/2014
NIH To Launch Phase I Of GlaxoSmithKline (GSK)'s Ebola Vaccine Candidate; NewLink Genetics VSV-EBOV 8/28/2014
Alkermes plc (ALKS) Announces Initiation Of Phase 1 Clinical Study Of ALKS 7106 For Treatment Of Pain 8/26/2014
BeiGene Co.,Ltd Enrolls First Patient In Phase 1 Study Of BGB-3111 8/26/2014
Oncothyreon Inc. (ONTY)'s Lung Cancer Drug EMR 63325-009 Misses Primary Endpoint In Phase 1 Study 8/20/2014
KalVista Pharmaceuticals Announces Start Of Clinical Development For Novel Treatment For Diabetic Macular Edema 8/20/2014
Enzymotec Announces Initiation Of A Clinical Study On Autism Spectrum Disorder 8/12/2014
GlaxoSmithKline (GSK) Will Take Its Shot At Ebola Later This Year 8/12/2014
Oramed Pharmaceuticals Inc. (ORMP) Reports Last Patient Out In Phase Iia Trial For ORMD-0801 In Type 1 Diabetes 8/7/2014
FDA Modifies Tekmira (TKMR)'s TKM-Ebola Clinical Hold To Partial Hold 8/7/2014
Prothena Corporation plc Release: Initiation Of Multiple Ascending Dose Phase 1 Study Of PRX002 In Patients With Parkinson's Disease 8/1/2014
AstraZeneca PLC (AZN) Steps Up Push Into Cancer Immunotherapy, Falls Behind Rivals Such As Bristol-Myers Squibb Company (BMY), Merck & Co., Inc. (MRK), And Roche (RHHBY) 7/31/2014
AFFiRiS AG Release: First Clinical Data Of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 7/31/2014
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Bavarian Nordic (BAVA.CO) Announces First Patient Treated In A Phase 1 Study Of MVA-BN® Brachyury In Advanced Cancer 7/24/2014
Tekmira Pharmaceuticals Corporation (TKMR) Provides Update on TKM-Ebola Phase I Clinical Hold 7/21/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
BioLineRx Ltd. Announces Results From Phase 1/2 Study For Celiac Treatment 7/16/2014
Novartis AG (NVS) To Test Alzheimer's Drugs In Patients Without Symptoms 7/15/2014
Probiodrug AG Presents Development Overview Of PQ912, Probiodrug’s QC-Inhibitor For Alzheimer’s Disease 7/10/2014
Novartis AG (NVS) Wins Breakthrough Status For New Leukemia Treatment CTL019 7/8/2014
Glenmark Pharmaceuticals's Novel Monoclonal Antibody GBR 830 For Treatment Of Autoimmune Diseases Entering Human Trials 7/3/2014
Tekmira Pharmaceuticals Corporation (TKMR) Sinks As The FDA Puts Ebola Study On Hold; Stock Down -15.54% At Market Close (July 3, 2014) 7/3/2014
GlycoVaxyn AG Announces The Initiation Of A Phase I Clinical Trial In Collaboration With Janssen Pharmaceutical Inc. For A Vaccine Against Extra-Intestinal Pathogenic Escherichia Coli Causing Urinary Tract Infection 7/1/2014
Hanmi Pharmaceutical, Co., Ltd And Collaborative Partner Kinex Pharmaceuticals Report Encouraging Results On Oraxol® For Patients With Advanced Gastric Cancer From A Phase I/II Clinical Study 6/30/2014
Bone Therapeutics Starts Patient Treatment In First Ever Clinical Trial With Allogeneic Bone Cell Therapy Product 6/25/2014
Debiopharm Announces Initiation Of A Phase I Study Of Debio 1450, An IV/Oral Potent Antibiotic Active Against Staphylococcal Infections 6/19/2014
Senhwa Biosciences Initiates Phase 1/2 Trial Of CX-4945 In Combination With Gemcitabine And Cisplatin 6/17/2014
Basilea Pharmaceutica (BSLN.SW) Initiates Phase 1 Combination Study With Its Gram-Negative Antibiotic BAL30072 And Meropenem 6/12/2014
InnFocus Highlights Clinical Results At The European Glaucoma Society Congress 6/11/2014
D-Pharm Ltd.'s Anti-Epileptic Drug DP-VPA Is Granted Fast Track Status By The Chinese Food And Drug Administration (CFDA) 6/9/2014
Medgenics, Inc. Announces First Patient Implanted In Phase 1/2 Clinical Trial Of MDGN-201 (EPODURE) 6/6/2014
AstraZeneca PLC (AZN) Shows Off Its Cancer Pipeline 6/4/2014
Basilea Pharmaceutica (BSLN.SW)'s Oncology Drug Candidate BAL101553 Shows First Evidence Of Antitumor Activity In Phase 1 Study 6/2/2014
Nanobiotix Presents Successful Phase I Results For Its Lead Nanomedicine Product NBTXR3 At American Society of Clinical Oncology 6/2/2014
Scancell: Update On Phase 1/2 Clinical Trial Of SCIB1 In Stage III/IV Melanoma 6/2/2014
Dilaforette Presents Results From Exploratory Phase 1/2 Clinical Trial In Uncomplicated Malaria 5/30/2014
Benitec Limited (BLT.AX) Commences Patient Dosing With TT-034 In Patients With Hepatitis C 5/29/2014
uniQure Announces Successful Transfection Of Liver Cells With AAV5 And Strong Safety Data From Acute Intermittent Porphyria Clinical Trial 5/27/2014
Propanc Health Group Targets Cancer Patient Trials in 2015 5/19/2014
AstraZeneca PLC (AZN) Cancer Drug Coveted By Pfizer Inc. (PFE) Works In Trial 5/16/2014
Oncos Therapeutics Ltd. Demonstrates Systemic, Tumor-Specific Immune Response by Local Administration of its Lead Product ONCOS-102 5/8/2014
Xspray Microparticles AB Announces Positive Phase I Data for HyNap™ Nilotinib 5/8/2014
Covagen Initiates Phase 1b/2a Study Of Bispecific Anti-TNF/IL-17A Fynomab COVA322 5/5/2014
Promising Results In Phase 1 Trial Lead immatics biotechnologies GmbH To Continue Work On Vaccine (IMA950) For Glioblastoma 4/23/2014
Aspireo Pharmaceuticals Reports Data In Further Phase Ib Study 4/22/2014
One Of A Kind Trial To Test 14 AstraZeneca PLC (AZN), Pfizer Inc. (PFE) Drugs At The Same Time 4/18/2014
Critical Pharmaceuticals Limited, The University of Nottingham And Nottingham University Hospitals NHS Trust Starts First Phase I Clinical Trial On A Nano-Enabled Intranasal Teriparatide For The Treatment Of Osteoporosis 4/15/2014
Vectura Group plc (VEC.L): FAVOLIR Regulatory Update 4/11/2014
Prothena Corporation plc Release: First Human Dosed In Phase 1 Study Of PRX002 For Treatment Of Parkinson's Disease 4/9/2014
Newron Pharmaceuticals (NWRN) Release: New Results With NW-3509 Presented At SIRS Conference 4/8/2014
Oxford BioMedica PLC (OXB.L) Completes Patient Recruitment Into Retinostat® Phase I Trial 4/7/2014
Novartis AG (NVS) Shows Off A Strong Pipeline Of 19 New Compounds At American Association for Cancer Research 4/4/2014
Kamada Ltd. (KMDA.TA) Announces U.S. Proof-Of-Concept Study With Glassia® For Graft-Versus-Host Disease 4/3/2014
Novaliq GmbH Announces Launch Of A Phase 1 Study Following US And European Patent Approval Of Cyclasol® (Cyclosporin) Eye Drops 4/3/2014
Innate Pharma (IPH.PA ) : Start Of Cohort Expansion Of Phase I Trial With Lirilumab And Nivolumab In Selected Solid Tumors 3/31/2014
e-Therapeutics plc Reports Positive Interim Results From UK Phase Ia Trial Of ETS2101 (Dexanabinol) In A Variety Of Solid Tumours 3/31/2014
Ability Pharmaceuticals Initiates Clinical Trial With Its Dual mTORC1/C2 Inhibitor ABTL0812 In Patients With Lung And Pancreatic Cancer 3/26/2014
Scancell: 8mg Higher Dose SCIB1 Study On Track 3/21/2014
Adocia Confirms Positive Clinical Results For Its Biochaperone® Combo, A Combination Of Long-Acting Insulin Glargine And Fast-Acting Insulin Lispro 3/20/2014
Hua Medicine Reports Strong Results For Early Diabetes Drug Trial 3/20/2014
GW Pharmaceuticals Provides Update on Cannabinoid Pipeline 3/17/2014
Betagenon AB: First Time In Man-AMPK Activator O304 3/10/2014
Adocia Announces Preliminary Positive Clinical Results For Its Combination Of Long-Acting Insulin Glargine And Fast-Acting Insulin Analog Lispro, Biochaperone® Combo 2/27/2014
GANYMED Pharmaceuticals AG's IMAB027 Enters Phase I/II Clinical Trial For Ovarian Cancer 2/12/2014
Nanobiotix: Sees Clinical Advance In Soft Tissue Sarcoma Pilot Trial With Lead Product, NBTXR3 Market Development Plan Outlined For Earlier Potential Launch In 2016 2/11/2014
THERAVECTYS Finalizes The Recruitment Of Patients For The Phase I/II Clinical Trial Of Its Anti-HIV Therapeutic Vaccine Candidate 2/5/2014
Bionomics Limited (BMICY.PK) Release: BNC105 Phase I/II Trial Achieves A High Response Rate In Ovarian Cancer 2/3/2014
Admedus Herpes Interim Phase I Results 2/3/2014
Orion Corporation Release: The Androgen Receptor Inhibitor ODM-201 - New Insights In The Treatment Of Prostate Cancer 2/3/2014
e-Therapeutics plc Temporary Halts Recruitment Into ETS2101 Cancer Trials 1/24/2014
Pluristem Therapeutics (PSTI)' Phase I/II Muscle Injury Trial Successfully Meets Primary Safety & Efficacy Endpoints 1/21/2014
Faron Pharmaceuticals Release: Promising New Treatment For Life Threatening Acute Respiratory Distress Syndrome (ARDS) 1/15/2014
Oxford BioMedica PLC (OXB.L) Announces Publication Of ProSavin® Phase I/II Study in The Lancet 1/10/2014
BrainStorm Cell Therapeutics Inc. Says Stem Cells Helped 75-Year Old Patient With ALS And MG 1/7/2014
Results Of Pluristem Therapeutics (PSTI)'s Phase 1/2 Muscle Injury Trial To Be Announced On January 21, 2014 1/6/2014
ARTES Biotechnology Release: TA101 GOCLIN European Funded Project For The Development Of An Innovative Product For The Treatment Of Rheumatoid Arthritis – 1,7M€ Total Budget 12/23/2013
Blaze Bioscience Inc. Announces Initiation Of First-In-Human Phase 1 Clinical Study Of BLZ-100 12/19/2013
BeiGene Co.,Ltd Enrolls First Patient In Phase 1 Study Of BGB-283 12/19/2013
BioLineRx Ltd. Enters Clinic With Novel Treatment For Celiac Disease 12/19/2013
BerGenBio AS Release: Data Highlights BGB324 As A Potential Novel Treatment Option For Drug Resistant Chronic Myeloid Leukemia 12/17/2013
Drawbridge Pharmaceuticals Initiates Clinical Trial For Phaxan™ 12/16/2013
CureVac GmbH Completes Patient Recruitment For Phase 2 Clinical Trial Of Mrna-Based Prostate Cancer Treatment 12/16/2013
MorphoSys AG Announces Additional Clinical Trial of MOR208 12/10/2013
Adaptimmune Ltd. Announces Interim Results From A Phase I/II Trial Of Engineered T Cells Targeting Cancer Testis Antigens In Multiple Myeloma 12/10/2013
Summit Corporation Announces First Patient Dosed In A Phase 1b Clinical Trial Of Smt C1100 For Treatment Of Duchenne Muscular Dystrophy 12/9/2013
Rhizen Pharmaceuticals S.A. Announces Initiation Of A "First In Human" Phase-1 Trial Of RP6530, A Dual PI3K Delta/Gamma Inhibitor, In Patients With Hematological Malignancies 12/6/2013
Anti-Cancer Program Originating From Lead Discovery Center Reaches Clinical Trials 12/5/2013
Galapagos NV (GLPG.BR) Reports Positive Phase 1 Results For GLPG1205 12/4/2013
VBL Therapeutics Receives FDA Fast Track Designation For Lead Compound VB-111 11/27/2013
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1 Study Of ISIS-GSK3 Rx And Earns $3 Million Milestone Payment From GlaxoSmithKline (GSK) 11/26/2013
Living Cell Technologies Ltd. Release: NTCELL Clinical Trial: Recruitment Of Further Patients Approved 11/25/2013
TopoTarget A/S Release: Final Results From CLN-14 Study In STS 11/20/2013
BioLineRx Ltd. Reports Publication In Peer Review Journal Of Positive Phase 1/2 Results In Stem Cell Mobilization For Multiple Myeloma 11/19/2013
Adocia Announces The Initiation Of A Clinical Trial On Its Combination Of The Long-Acting Insulin Glargine And A Fast-Acting Insulin Analog 11/13/2013
PROMETHERA Biosciences S.A./N.V. Successfully Enrols Twenty Patients In Its Multicentric Phase I/II Trial 11/12/2013
Gentium S.p.A. Announces Successful Completion Of Defibrotide Phase 1 Study In Japan 11/12/2013
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM) -Study Features THC and CBD as the Primary Cannabinoids 11/11/2013
FDA Grants Orphan Drug Status for PAT-SM6 11/6/2013
Swedish Orphan Biovitrum Hosts Capital Market Day Event - Announces Phase I Complement Inhibitor Programs 11/5/2013
Canbex Therapeutics Commences Phase I Clinical Trial of Lead Product VSN16R as a Potential Treatment for Spasticity in Multiple Sclerosis 11/4/2013
SEEK Announces Publication of HIV-v Data in Vaccine Journal 11/1/2013
CEVEC Pharma Release: Completion of a "First in Human" Clinical Phase I Study With a Therapeutic Protein Derived From CAP® Cells 11/1/2013
New Two-Hormone Roche (RHHBY) Drug Shows Promise in Diabetes, Obesity 11/1/2013
Kamada Ltd. (KMDA.TA) Reports New Data From an Extension Study of Its Phase I/II Trial With Glassia in Pediatric Patients With Type 1 Diabetes 10/31/2013
ISA Pharmaceuticals Initiates Phase I/II Clinical Trial With ISA101 in Women With Cervical Cancer 10/29/2013
Clovis Oncology (CLVS)'s CO-1686 Continues to Demonstrate Promising Clinical Activity and Safety in Updated Phase I Study Results 10/28/2013
Immunicum Doses the First Patient in a New Clinical Phase I/II-Study in Primary Liver Cancer 10/23/2013
Galapagos NV (GLPG.BR) Presents Superior Potentiator Series for CF 10/17/2013
Oxford BioMedica PLC (OXB.L) Receives Agreement From FDA and ANSM to Resume Recruitment Into Ocular Clinical Trials 10/17/2013
Galapagos NV (GLPG.BR) to Present Phase 1 Data on FFA2 Antagonist GLPG0974 at UEG Week in Berlin 10/16/2013
Protalix Biotherapeutics, Inc. (PLX) Announces Positive Phase I Clinical Trial Results for Oral GCD in Gaucher Disease Patients 10/14/2013
Sihuan Pharmaceutical Holdings Group Ltd. Approved for China Trials of Innovative Cancer Drug 10/11/2013
Karolinska Development AB: Pergamum Announces Final Data From Phase I/II Study of LL-37 in Patients With Chronic Leg Ulcers 10/10/2013
Medivir AB (MVIRb.F) Release: Positive Results From a Phase I Study With MIV-711 for the Treatment of Osteoarthritis and Other Bone Related Disorders 10/9/2013
Scancell Release: Investor Update Showcases Moditope® Platform and Updates SCIB1 Trial Progress 10/1/2013
Tesaro, Inc. Describes Initial Phase 1 Clinical Data for TSR-011 Presented at the European Cancer Congress 2013 9/30/2013
BerGenBio AS Study Published in Blood Highlights Axl Inhibition as a Novel Therapeutic Approach for Acute Myeloid Leukemia 9/30/2013
Ariad Pharmaceuticals, Inc. (ARIA) Presents Updated Phase 1/2 Data on AP26113 in Patients With Non-Small Cell Lung Cancer 9/30/2013
To-BBB technologies BV Presents Clinical Data on Lead Product 2B3-101 9/26/2013
Living Cell Technologies Ltd. Release: First-in-Man' Implant of Regenerative Cell Therapy in Parkinson's Disease 9/24/2013
Versartis, Inc. Presents Latest Positive Results From Its Pediatric Study of Long-Acting Growth Hormone Treatment at International Endocrinology Conference 9/23/2013
Skyepharma PLC (SKYEF) Release: Flutiform Trial for COPD Initiated in Europe 9/19/2013
ISA Pharmaceuticals Initiates Phase I/II Clinical Trial of ISA101 in Patients With Anal Intraepithelial Neoplasia (AIN) 9/16/2013
Wanbang Biopharmaceuticals to Begin Clinical Trial of Fast-Acting Insulin Analogue 9/16/2013
Patrys Limited (PAB.AX) Release: PAT-SM6 Receives Orphan Drug Designation for Multiple Myeloma in Europe 9/12/2013
Dompe Announces the FDA Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa 9/11/2013
Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT 9/10/2013
Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors 9/9/2013
Gamida Cell Ltd. Announces the Successful Transplantation of the First Patient in the Company's Phase I/II Study of NiCord® in a Single Cord Configuration 9/9/2013
ProSensa Holding N.V. Initiates First Patient Dosing in Phase I/II trial of PRO053 9/6/2013
Hua Medicine Begins Phase I Trial of Novel Diabetes Treatment 9/6/2013
Apitope Announces Positive Results From Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis 9/3/2013
Imaxio Announces the First Human Clinical Trial Using Its Pro-Immunogenic Technology IMX313 in Tuberculosis 9/3/2013
Congenia Announces Enrollment of First Healthy Volunteer in Phase 1 Clinical Trial of GNX-5086 8/27/2013
Karolinska Development AB: Lipidor Reports Positive Clinical Phase I/II Data in Psoriasis 8/27/2013
Lipidor Reports Positive Clinical Phase I/II Data in Psoriasis 8/27/2013
Oncolytic Virus Specialist Virttu Biologics Confirms Treatment of First Cohort of Patients in Phase I/II SEPREHVIR® Study in Mesothelioma 8/26/2013
Patrys Limited (PAB.AX) Release: Data From 2nd and 3rd Cohorts of Patients in Multiple Myeloma Clinical Trial 8/13/2013
Trophos Completes Patient Enrolment in a First Study of Olesoxime in Relapsing Remitting Multiple Sclerosis 8/7/2013
Patrys Limited (PAB.AX)'s Multiple Myeloma Clinical Trial to Progress to Final Patient Group 8/7/2013
AllaChem Announces the Beginning of Phase I Clinical Studies of AV4025, a Potent Small Molecule for the Treatment of Chronic Hepatitis C Infection 8/5/2013
Boehringer Ingelheim Corporation Release: First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for linagliptin in Type 2 Diabetes 7/31/2013
uniQure Announces Start of Parkinson's Disease Gene Therapy Phase I Trial by University of California, San Francisco (UCSF)/National Institutes of Health (NIH) to Test Its GDNF Gene in Patients 7/29/2013
PRANA Biotechnology (PRAN) Doses First Patient in PBT2 Alzheimer's Extension Study 7/29/2013
Patrys Limited (PAB.AX) Completes Treatment of Third Patient Group in Multiple Myeloma Trial 7/25/2013
Adaptimmune Ltd. Announces Opening of Phase I/IIa Clinical Trial in Ovarian Cancer 7/25/2013
Immunicum AB Release: The Medical Products Agency Clears Unique Swedish Cancer Vaccine for Clinical Tests in Liver Cancer Patients 7/22/2013
TopoTarget A/S Release: Belinostat Gets European Orphan Drug Designation for the Treatment of Malignant Thymomas 7/18/2013
Alize Pharma Launches the First Phase I Clinical Trial for AZP-531, Its Unacylated Ghrelin Analog, in Type 2 Diabetes 7/16/2013
Probiodrug AG Provides Update on Clinical Development of PQ912, Its Most Advanced QC-Inhibitor for Alzheimer's Disease 7/16/2013
Vernalis PLC (VNLPY.PK) Initiates Phase Ib/II POC Study of V81444 7/12/2013
Scancell SCIB1 8mg Study Update 7/12/2013
Pluristem Therapeutics (PSTI) Completes Enrollment for Phase I/II Muscle Injury Trial 7/11/2013
Ablynx Starts Additional Phase I Studies With Anti-RSV Nanobody ALX-0171 7/8/2013
Immunomedics, Inc. (IMMU) Reports First Results From Phase Ib Study of 90Y-Clivatuzumab in Patients With Metastatic Pancreatic Cancer After 2 or More Prior Therapies 7/3/2013
CLL Pharma and Leurquin-Mediolanum Announce Initiation of Phase 1b Clinical Trial of the Compound Syn1002 in Pain 7/2/2013
GlaxoSmithKline (GSK) Muscular Dystrophy Drug Gets "Breakthrough" Status 6/28/2013
Edge Therapeutics Reports Positive Early Clinical Experience With EG-1962 to Prevent Serious Complications After Brain Hemorrhage 6/27/2013
Mirna Therapeutics, Inc. and Horizon Discovery Ltd. Publication Elucidates Novel miR-34 Tumor Suppressor Pathway, Underscores miR-34 as Important Anticancer Approach 6/26/2013